WO2009036996A3 - Small molecule bradykinin b1 receptor antagonists - Google Patents

Small molecule bradykinin b1 receptor antagonists Download PDF

Info

Publication number
WO2009036996A3
WO2009036996A3 PCT/EP2008/007919 EP2008007919W WO2009036996A3 WO 2009036996 A3 WO2009036996 A3 WO 2009036996A3 EP 2008007919 W EP2008007919 W EP 2008007919W WO 2009036996 A3 WO2009036996 A3 WO 2009036996A3
Authority
WO
WIPO (PCT)
Prior art keywords
bradykinin
small molecule
receptor antagonists
compounds
pain
Prior art date
Application number
PCT/EP2008/007919
Other languages
French (fr)
Other versions
WO2009036996A2 (en
Inventor
Elsa Locardi
Klaus Dinkel
Marco Schaudt
Uwe Richter
Dirk Scharn
Gerd Hummel
Ulrich Reineke
Ulf Reimer
Original Assignee
Jerini Ag
Elsa Locardi
Klaus Dinkel
Marco Schaudt
Uwe Richter
Dirk Scharn
Gerd Hummel
Ulrich Reineke
Ulf Reimer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jerini Ag, Elsa Locardi, Klaus Dinkel, Marco Schaudt, Uwe Richter, Dirk Scharn, Gerd Hummel, Ulrich Reineke, Ulf Reimer filed Critical Jerini Ag
Priority to EP08802425A priority Critical patent/EP2195288A2/en
Priority to JP2010525265A priority patent/JP2010539204A/en
Priority to CA2700051A priority patent/CA2700051A1/en
Priority to AU2008300822A priority patent/AU2008300822A1/en
Publication of WO2009036996A2 publication Critical patent/WO2009036996A2/en
Publication of WO2009036996A3 publication Critical patent/WO2009036996A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/06—Compounds containing any of the groups, e.g. semicarbazides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Disclosed are compounds of formula (I) which are bradykinin B1 receptor (B1R) antagonists. These compounds are useful to treat diseases or relieve adverse symptoms associated with inflammation and pain. The invention encompasses novel compounds and acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases involving inflammation and pain.
PCT/EP2008/007919 2007-09-19 2008-09-19 Small molecule bradykinin b1 receptor antagonists WO2009036996A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP08802425A EP2195288A2 (en) 2007-09-19 2008-09-19 Small molecule bradykinin b1 receptor antagonists
JP2010525265A JP2010539204A (en) 2007-09-19 2008-09-19 Small molecule bradykinin B1 receptor antagonist
CA2700051A CA2700051A1 (en) 2007-09-19 2008-09-19 Small molecule bradykinin b1 receptor antagonists
AU2008300822A AU2008300822A1 (en) 2007-09-19 2008-09-19 Small molecule bradykinin B1 receptor antagonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07018396 2007-09-19
EP07018396.7 2007-09-19

Publications (2)

Publication Number Publication Date
WO2009036996A2 WO2009036996A2 (en) 2009-03-26
WO2009036996A3 true WO2009036996A3 (en) 2009-06-18

Family

ID=40268352

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/007919 WO2009036996A2 (en) 2007-09-19 2008-09-19 Small molecule bradykinin b1 receptor antagonists

Country Status (7)

Country Link
EP (1) EP2195288A2 (en)
JP (1) JP2010539204A (en)
AR (1) AR068509A1 (en)
AU (1) AU2008300822A1 (en)
CA (1) CA2700051A1 (en)
TW (1) TW200930710A (en)
WO (1) WO2009036996A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2722704A1 (en) * 2008-04-28 2009-11-05 Zalicus Pharmaceuticals Ltd. Cyclylamine derivatives as calcium channel blockers
EP2344176A1 (en) * 2008-09-18 2011-07-20 Jerini AG Use of bradykinin b1 receptor antagonists in intestinal fibrosis treatment
SG185524A1 (en) 2010-05-12 2012-12-28 Vertex Pharma Compounds useful as inhibitors of atr kinase
MX2012015023A (en) * 2010-06-30 2013-04-03 Fujifilm Corp Novel nicotinamide derivatives or salts thereof.
US8937073B2 (en) 2010-08-20 2015-01-20 Boehringer Ingelheim International Gmbh Disubstituted tetrahydrofuranyl compounds and their use as B1-receptor antagonists
HUP1000598A2 (en) 2010-11-05 2012-09-28 Richter Gedeon Nyrt Indole derivatives
RU2576623C2 (en) 2011-12-28 2016-03-10 Фуджифилм Корпорэйшн Novel nicotinamide derivative or its salt
BR102014028162A2 (en) * 2013-11-12 2015-09-08 Dow Agrosciences Llc process for fluorination of compounds
US20210317092A1 (en) 2016-12-23 2021-10-14 Bayer Pharma Aktiengesellschaft Tetrazole containing compounds
JOP20190156B1 (en) 2016-12-23 2023-09-17 Bayer Pharma AG Carboxylic acid aromatic amides as antagonists of bradykinin b1 receptor
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
AR118982A1 (en) * 2019-05-23 2021-11-17 Pharvaris Gmbh CYCLIC BRADYKININ RECEPTOR ANTAGONISTS
TW202229258A (en) * 2020-09-29 2022-08-01 日商日本歐愛特農業科技股份有限公司 Novel piperazine compound or the salt thereof
WO2024059495A1 (en) * 2022-09-12 2024-03-21 The Regents Of The University Of California Methods of preparing ergoline analogs

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3795678A (en) * 1961-06-09 1974-03-05 Hoffmann La Roche Alpha-2-methylhydrazine-pyridinotoluidides and derivatives
US4950668A (en) * 1987-04-24 1990-08-21 Mitsubishi Kasei Corporation Pyrazole derivative, insecticidal or miticidal composition containing the same as the effective ingredient
US5098900A (en) * 1984-12-10 1992-03-24 Nissan Chemical Industries Ltd. 3(2h)pyridazinone, process for its preparation and anti-allergic agent containing it
US5216165A (en) * 1990-10-03 1993-06-01 American Home Products Corporation N-substituted aminoquinolines as analgesic agents
WO2000051973A1 (en) * 1999-03-04 2000-09-08 Sanofi-Synthelabo Cyclobutene-3,4-dione derivatives, preparation method and therapeutic use
WO2000063170A1 (en) * 1999-04-20 2000-10-26 Sanofi-Synthelabo Cyclobutene-3,4-dione derivatives as inhibitors of phosphodiesterase 5
EP1300398A1 (en) * 2000-07-05 2003-04-09 Yamanouchi Pharmaceutical Co. Ltd. Propane-1,3-dione derivatives
WO2003055866A1 (en) * 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
WO2004041788A1 (en) * 2002-11-02 2004-05-21 Aventis Pharma Deutschland Gmbh Novel pyrimidine-4,6-dicarboxamides for the selective inhibition of collagenases
US20040235753A1 (en) * 2001-06-25 2004-11-25 Pitt Gray Robert William Oxytocin agonists
US20050245503A1 (en) * 2001-12-19 2005-11-03 Yun-Xing Cheng Therapeutic heterocycles
US20050261327A1 (en) * 2004-05-20 2005-11-24 Bock Mark G 2-(Bicyclo)alkylamino-derivatives as mediatores of chronic pain and inflammation
US20070032529A1 (en) * 2005-05-23 2007-02-08 Japan Tobacco Inc. Pyrazole compounds and their use as antidiabetes agents
US20070155739A1 (en) * 2005-12-30 2007-07-05 Alantos Pharmaceuticals, Inc. Substituted bis-amide metalloprotease inhibitors
WO2007129195A2 (en) * 2006-05-04 2007-11-15 Pfizer Products Inc. 4-pyrimidine-5-amino-pyrazole compounds
WO2008123582A1 (en) * 2007-04-04 2008-10-16 Kowa Company, Ltd. Tetrahydroisoquinoline compound

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ240863A (en) * 1991-09-11 1995-04-27 Mcneilab Inc Substituted 4-aryl piperidine and 4-aryl piperazine derivatives, preparation and pharmaceutical compositions thereof
CN100558718C (en) * 2002-10-23 2009-11-11 詹森药业有限公司 Piperazinyl and diazacyclo heptyl benzene methane amide and thiobenzamide
WO2005014576A1 (en) * 2003-08-12 2005-02-17 Takeda Pharmaceutical Company Limited Isoquinolinone derivative, process for producing the same and use thereof
WO2005035534A1 (en) * 2003-10-08 2005-04-21 Ono Pharmaceutical Co., Ltd. Heterocyclic bicyclo ring and heterocyclic tricyclo ring compounds and drugs comprising the same
JP2007191461A (en) * 2005-05-23 2007-08-02 Japan Tobacco Inc Pyrazole compound and antidiabetic containing the same

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3795678A (en) * 1961-06-09 1974-03-05 Hoffmann La Roche Alpha-2-methylhydrazine-pyridinotoluidides and derivatives
US5098900A (en) * 1984-12-10 1992-03-24 Nissan Chemical Industries Ltd. 3(2h)pyridazinone, process for its preparation and anti-allergic agent containing it
US4950668A (en) * 1987-04-24 1990-08-21 Mitsubishi Kasei Corporation Pyrazole derivative, insecticidal or miticidal composition containing the same as the effective ingredient
US5216165A (en) * 1990-10-03 1993-06-01 American Home Products Corporation N-substituted aminoquinolines as analgesic agents
WO2000051973A1 (en) * 1999-03-04 2000-09-08 Sanofi-Synthelabo Cyclobutene-3,4-dione derivatives, preparation method and therapeutic use
WO2000063170A1 (en) * 1999-04-20 2000-10-26 Sanofi-Synthelabo Cyclobutene-3,4-dione derivatives as inhibitors of phosphodiesterase 5
EP1300398A1 (en) * 2000-07-05 2003-04-09 Yamanouchi Pharmaceutical Co. Ltd. Propane-1,3-dione derivatives
US20040235753A1 (en) * 2001-06-25 2004-11-25 Pitt Gray Robert William Oxytocin agonists
US20050245503A1 (en) * 2001-12-19 2005-11-03 Yun-Xing Cheng Therapeutic heterocycles
WO2003055866A1 (en) * 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
WO2004041788A1 (en) * 2002-11-02 2004-05-21 Aventis Pharma Deutschland Gmbh Novel pyrimidine-4,6-dicarboxamides for the selective inhibition of collagenases
US20050261327A1 (en) * 2004-05-20 2005-11-24 Bock Mark G 2-(Bicyclo)alkylamino-derivatives as mediatores of chronic pain and inflammation
US20070032529A1 (en) * 2005-05-23 2007-02-08 Japan Tobacco Inc. Pyrazole compounds and their use as antidiabetes agents
US20070155739A1 (en) * 2005-12-30 2007-07-05 Alantos Pharmaceuticals, Inc. Substituted bis-amide metalloprotease inhibitors
WO2007129195A2 (en) * 2006-05-04 2007-11-15 Pfizer Products Inc. 4-pyrimidine-5-amino-pyrazole compounds
WO2008123582A1 (en) * 2007-04-04 2008-10-16 Kowa Company, Ltd. Tetrahydroisoquinoline compound

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 16 August 2006 (2006-08-16), XP002512766, retrieved from STN Database accession no. 901750-58-1 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 17 July 2006 (2006-07-17), XP002523384, retrieved from STN Database accession no. 893748-03-3 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 21 August 2006 (2006-08-21), XP002512765, retrieved from STN Database accession no. 902939-75-7 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 22 August 2006 (2006-08-22), XP002523301, retrieved from STN Database accession no. 903169-03-9 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 7 June 2004 (2004-06-07), XP002523302, retrieved from STN Database accession no. 690245-28-4 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 7 June 2004 (2004-06-07), XP002523303, retrieved from STN Database accession no. 690245-29-5 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 8 June 2004 (2004-06-08), XP002523304, retrieved from STN Database accession no. 690644-01-0 *
OKANO ATSUJI ET AL: "Medicinal chemical studies on antiplasmin drugs. 4. Chemical modification of trans-4-aminomethylcyclohexanecarboxylic acid and its effect on antiplasmin activity", JOURNAL OF MEDICINAL CHEMISTRY, US AMERICAN CHEMICAL SOCIETY. WASHINGTON, vol. 15, no. 3, 1 January 1972 (1972-01-01), pages 247 - 255, XP002317573, ISSN: 0022-2623 *
RUAN Z ET AL: "Phenylsilane as an active amidation reagent for the preparation of carboxamides and peptides", TETRAHEDRON LETTERS, ELSEVIER, AMSTERDAM, vol. 47, no. 43, 23 October 2006 (2006-10-23), pages 7649 - 7651, XP025005166, ISSN: 0040-4039, [retrieved on 20061023] *
STOLL VINCENT ET AL.: "Influenza neuraminidase inhibitors: structure-based design of a novel inhibitor series", BIOCHEMISTRY, vol. 42, no. 3, 2003, pages 718 - 727, XP002512764 *

Also Published As

Publication number Publication date
TW200930710A (en) 2009-07-16
JP2010539204A (en) 2010-12-16
EP2195288A2 (en) 2010-06-16
AR068509A1 (en) 2009-11-18
AU2008300822A1 (en) 2009-03-26
WO2009036996A2 (en) 2009-03-26
CA2700051A1 (en) 2009-03-26

Similar Documents

Publication Publication Date Title
WO2009036996A3 (en) Small molecule bradykinin b1 receptor antagonists
WO2008079291A3 (en) Substituted heterocycles and methods of use
MX2009006543A (en) Heterocyclic compounds and their use in treating inflammation, angiogenesis and cancer.
WO2009091374A3 (en) Fused heterocyclic derivatives and methods of use as c-met inhibitors
WO2007005668A3 (en) Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer
WO2010022055A3 (en) 1, 3, 5 -triaz ine derivatives useful in the treatment of chronic pain disorders
MX2009008531A (en) Nitrogen-containing heterocyclyl ketones and methods of use.
WO2008086014A3 (en) Bis-aryl amide derivatives useful for the treatment of cancer
WO2008157751A3 (en) Substituted imidazoheterocycles
MD20140059A2 (en) Substituted 4-phenyl-pyridines for the treatment of NK-1 receptor related diseases
GEP20125624B (en) Pyridazine derivatives as smo inhibitors
WO2006106326A8 (en) Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
WO2010011772A3 (en) Tri-cyclic pyrazolopyridine kinase inhibitors
NO20084652L (en) Deazapurins useful as inhibitors of januskinases
EA025086B9 (en) Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases
MY167135A (en) Fused heterocyclic derivatives and methods of use
WO2010042925A3 (en) Compositions and methods for treating alcohol use disorders, pain and other diseases
PL2150530T3 (en) Substituted sulfonamide derivatives
WO2009132202A3 (en) Macrocyclic compounds and their use as kinase inhibitors
WO2007048070A3 (en) Pyrrolo-pyridine derivatives for the treatment of cancer diseases
WO2007035620A3 (en) Carbazole derivatives
WO2009082038A3 (en) Ampa receptor antagonists and zonisamide for epilepsy
MX2012000166A (en) Phosphorus containing quinazoline compounds and methods of use.
GEP20135806B (en) Lactams as beta secretase inhibitors
MX2008013212A (en) 4-anilinoquinoline-3-carboxamides as csf-1r kinase inhibitors.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08802425

Country of ref document: EP

Kind code of ref document: A2

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2008300822

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2700051

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010525265

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008802425

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008300822

Country of ref document: AU

Date of ref document: 20080919

Kind code of ref document: A